Shots:
- Health Canada has approved Empaveli (pegcetacoplan) for patients (≥12yrs.) with C3 glomerulopathy (C3G) or primary IC-MPGN to reduce proteinuria, marking the first approved therapy for these indications in Canada
- Approval was based on the P-III (VALIANT) study, where Empaveli demonstrated a 68% reduction in proteinuria (uPCR), stabilization of kidney function, and clearance of C3 deposits, meeting key endpoints
- Pegcetacoplan is a targeted C3 complement inhibitor co-developed by Sobi and Apellis, designed to regulate complement cascade activation in rare kidney diseases
Ref: GlobeNewswire | Image: Sobi | Press Release
Related News: Sobi Reports the EC Approval of Aspaveli for C3 Glomerulopathy and Primary IC-MPGN
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
